Navigation Links
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
Date:4/21/2009

atinum chemotherapy drugs. Picoplatin has demonstrated anti-tumor activity in a variety of solid tumors. It is being studied in multiple cancer indications, treatment combinations and by two routes of administration.

Poniard is currently evaluating the efficacy and safety of picoplatin in SCLC in the pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial, which is being conducted under a Special Protocol Assessment agreement with the U.S. Food and Drug Administration. The Company reached its enrollment target in this international, multi-center, randomized, controlled trial in March 2009. Poniard is also evaluating picoplatin in two Phase 2 clinical trials -- one in patients with metastatic CRC and the other in patients with castration-resistant (or hormone-refractory) prostate cancer.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's results of clinical trials, business objectives and strategic goals, drug development plans, the potential safety and efficacy of its products in development and commercialization strategy. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of clinical testing; the receipt and timing of FDA and other required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating l
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Poniard Pharmaceuticals Announces Upcoming Conference Participation
2. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
3. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
4. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
5. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
6. Poniard Pharmaceuticals Receives Going Concern Qualification
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
9. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 UT Southwestern Medical ... selectively and irreversibly interferes with the activity of ... of tumors. , The molecule, SML-8-73-1 (SML), interferes ... viral oncogene homolog. The gene produces proteins called ... K-Ras can result in normal cells dividing uncontrollably ...
(Date:7/28/2014)... 28, 2014 Lourdes Health System has ... and reduced wait times for veterans needing medical care. ... in the state—and the only one in Camden, Burlington ... Community Care program (PC3). PC3 gives veterans access to ... cannot provide services due to lack of available specialists, ...
(Date:7/28/2014)... July 28, 2014 The report, ... & Geography - Trends and Forecasts to 2019” ... with analysis and forecasting of the global consumption ... market data tables with 39 figures spread through ... Market"., http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are ...
(Date:7/28/2014)... 28, 2014 The American ... of professionals engaged in the field of organ ... Transplantation and Immunology Research Network (TIRN), a ... research. As modern organ transplantation continues to diversify, ... could provide more opportunities for physicians, scientists and ...
(Date:7/28/2014)... with one of the UK,s most common respiratory diseases ... pulmonary disease (COPD) is the name for a collection ... damage to the lungs. Often linked to smoking, ... hospital admissions in the UK, with a high proportion ... discharged. , A team of researchers, led ...
Breaking Medicine News(10 mins):Health News:UTSW cancer researchers identify irreversible inhibitor for KRAS gene mutation 2Health News:Lourdes Expands Military Partnership with Veterans 2Health News:Lourdes Expands Military Partnership with Veterans 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 2Health News:American Society of Transplantation (AST) Launches Transplantation and Immunology Research Network (TIRN); Aims to Expand Research Collaboration & Funding 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3
... Children,s Research Hospital investigators have found that an electrically ... is critical to the acute hearing of humans and ... how hearing loss can result from malfunction of this ... drugs such as aspirin. , Sound entering the cochlea ...
... $12 Million in Series A First Tranche Financing, ... Capital announced,today the formation of ACT Biotech Inc., a ... drugs. ACT Biotech has,entered into a license agreement with ... stage oncology assets. In conjunction with the,agreement, ACT has ...
... Reality, MANHATTAN BEACH, Calif., May 7 A ... 2006 continues,today with open hearings and fact-finding in California. ... how homecare and nursing home,workers in the long term ... greatest strength to win for their families and the,clients ...
... MECHANICSBURG, Pa., May 7 Select Medical Corporation,will release ... 31,2008 on Thursday, May 15, 2008., The Company ... on Wednesday, May 21, 2008, at 11:00am EDT. The ... international dial in number is,1-210-839-8503. The passcode for the ...
... neural development, mouse study shows , , WEDNESDAY, May 7 ... that suppresses appetite by blocking cannabinoid receptors in the ... scientists report. , In research with mice, they found ... of the brain necessary for neural development in young ...
... may increase adults risk for having dementia, according to ... Health. Their analysis of published obesity and dementia ... a consistent relationship between the two diseases. The results ... of Obesity in the May, 2008 issue of Obesity ...
Cached Medicine News:Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 2Health News:St. Jude finds 'dancing' hair cells are key to humans' acute hearing 3Health News:ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare 2Health News:Open Hearings, Fact-Finding Today by SEIU Long Term Care Workers Continues Democratic Process Begun in 2006 2Health News:Obesity linked to increased risk for dementia 2
(Date:7/25/2014)... , July 25, 2014  Corporate libraries are ... understanding new advancements in technology and how to cope ... libraries in the pharmaceutical and medical device industries are ... the information and services they provide. ... LLC there are many forces of change that leading ...
(Date:7/25/2014)... /PRNewswire-iReach/ -- "Australia Capsule Endoscopy Systems Market Outlook to ... Endoscopy Systems market. The report provides value, in millions ... (in US dollars) within market segments: Photo ... Endoscopes , Capsule Endoscopy Data Recorders , ... provides company shares and distribution shares data for each ...
(Date:7/25/2014)...  Smile Train and its technology partner BioDigital have ... Simulator among leading global health innovations in The Hive ... Washington, D.C. at The John F. ... "Smile Train is honored to be represented through our ... in health and medicine that TEDMED unites each year," ...
Breaking Medicine Technology:Forces of Change Reshaping Corporate Libraries & Information Services 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 2Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 3Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 4Australia Capsule Endoscopy Systems Market Analysis and Forecast to 2020 5Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 2Smile Train and BioDigital Selected to Showcase Virtual Surgery Simulator in The Hive at TEDMED 2014 3